Organon & Co.: directors' dealings · United States · SEC (Form 4)

About Organon & Co.

Organon & Co. (NYSE: OGN) is a U.S.-listed healthcare company headquartered in Jersey City, New Jersey, United States. It was created in 2021 as a spin-off from Merck, and it has since built a business model centered on women’s health, supported by a portfolio of biosimilars and established brands. For investors, Organon is best viewed as a specialty pharmaceutical company with a defensive profile, but also with meaningful exposure to pricing pressure, loss of exclusivity, and commercial execution. The company’s operations are organized into three main portfolios: Women’s Health, Biosimilars, and Established Brands. Women’s Health is Organon’s strategic core and includes contraceptive and fertility products such as Nexplanon, NuvaRing, Follistim AQ, and Elonva. The Biosimilars portfolio spans immunology and oncology-related therapies, including Hadlima, Renflexis, Ontruzant, Tofidence, as well as newer U.S. launches such as Bildyos and Bilprevda. The Established Brands segment includes products across dermatology, respiratory, cardiovascular, and non-opioid pain management, with brands such as Emgality and Vtama among the better-known assets. This mix gives Organon both a focus franchise and a broad base of mature products. Geographically, Organon has a highly international footprint. The company distributes products in more than 140 countries and territories, and most of its revenue is generated outside the United States. That global reach is an advantage because it diversifies the business across markets, but it also introduces exposure to foreign exchange movements, local reimbursement systems, and regulatory complexity. In competitive terms, Organon is differentiated by its leadership ambitions in women’s health, where it benefits from brand recognition and established commercial relationships, while still facing strong generic and biosimilar competition in other parts of the portfolio. Recent developments are important for investors following the stock. Organon reported full-year 2025 revenue of about $6.2 billion and emphasized balance-sheet improvement and deleveraging actions. The company also completed the divestiture of the JADA system in January 2026. In addition, management disclosed that its audit committee is reviewing certain prior-year biosimilar purchasing timing matters. Most notably, in April 2026, Organon announced a definitive agreement to be acquired by Sun Pharma in an all-cash transaction, making this a particularly significant event for OGN on the NYSE in the United States.